Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (22510)	9/24/1999 11:19:00 PM
From: Greg22	Read Replies (1) \| Respond to of 23519

Frostman, From what I understand about Alibra, it has many advantages over Muse. Surprisingly, it seams that we have heard very little about this product from Vivus. It is my opinion that this product could help Vivus recapture market share from Pfizer. Here are some advantages of Alibra... 1.) No titration necessary. 2.) One dose (125mg?) with the efficacy of 1000mg of Muse. 3.) Lesser side effects. 4.) Lesser production costs and,therefore, greater margins. 5.) Not certain about this, but I believe there will be milestones from AZ. Basically, Alibra offers more bang for the buck.